Osivax
Osivax is a clinical-stage French biopharmaceutical company developing universal vaccines against influenza, sarbecoviruses, and HPV using its proprietary oligoDOM™ self-assembling nanoparticle platform. It serves governments, global health agencies, and pharmaceutical partners through grants, equity financing, and regional licensing.
- Company typePrivate
- Founded2017
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Osivax does
Osivax SAS is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Lyon, France, with operating subsidiaries in Liège, Belgium and Melbourne, Australia. The company develops universal vaccines targeting highly conserved internal antigens of mutating pathogens using its proprietary oligoDOM™ self-assembling nanoparticle platform, which is engineered to elicit potent CD8+ T-cell responses alongside B-cell immunity. Its lead candidate, OVX836, is a broad-spectrum influenza A vaccine that targets the nucleoprotein rather than the conventional hemagglutinin surface antigen; it has progressed through seven clinical trials involving more than 4,000 participants, with a Phase 2a study demonstrating 84% protection against PCR-confirmed symptomatic influenza (published in The Lancet Infectious Diseases, July 2023). The pipeline also includes OVX033, a universal sarbecovirus vaccine candidate, and PANHPVAX, a pan-strain HPV vaccine co-developed with DKFZ in Germany.
The company's business model rests on three pillars: non-dilutive grant funding from agencies such as BARDA ($19.5M, August 2025), NIAID ($1.5M+, December 2023), Bpifrance (€10M, June 2022), and the Bill & Melinda Gates Foundation; equity financing through a Series A round of €8M in July 2019 led by Noshaq and a Series B round of €10M in March 2025 with Meiji Seika Pharma; and regional licensing and commercialization partnerships, most notably an exclusive license option granted to KM Biologics (Meiji Group) for Japan in September 2024. Osivax currently has no commercial products and generates no product revenue; future distribution is planned through pharmaceutical licensees and government procurement channels. Customer segments are governments, global health agencies, and large pharmaceutical partners seeking differentiated vaccine assets for pandemic preparedness and seasonal influenza portfolios.
Osivax firmographics
Firmographics- Name
- Osivax
- Legal name
- Osivax SAS
- Website
- https://osivax.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Osivax is a clinical-stage French biopharmaceutical company developing universal vaccines against influenza, sarbecoviruses, and HPV using its proprietary oligoDOM™ self-assembling nanoparticle platform. It serves governments, global health agencies, and pharmaceutical partners through grants, equity financing, and regional licensing.
- Ownership category
- akta.pro rank
Osivax industry classification
Industry- Product category
- Biopharmaceutical Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industry
- Adult Vaccines (HLAIAEAB)
Keywords
Where Osivax is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
Osivax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Vaccine Product Sales: Osivax is developing a pipeline of universal influenza vaccines (OVX836, OVX033) intended for commercialization. The company aims to provide broad-spectrum protection against influenza and other mutating viruses through its proprietary vaccine candidates.
- Licensing and Partnership Agreements: Osivax generates non-dilutive funding through licensing agreements with pharmaceutical partners such as KM Biologics for Japan rights, and collaborates with global health agencies and pharmaceutical companies for co-development and commercialization.
- Government and NGO Grants: Osivax receives significant non-dilutive funding from government agencies (BARDA $19.5M, Bpifrance €10M, NIAID $1.5M+) and foundations (Bill & Melinda Gates Foundation) to support vaccine development programs.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Osivax product offering
Product offeringCore offering
Osivax develops universal vaccine candidates using its proprietary oligoDOM™ self-assembling nanoparticle platform, which targets highly conserved internal antigens (nucleoprotein/nucleocapsid) to elicit potent T-cell and B-cell immune responses. Its lead candidates include OVX836 (broad-spectrum influenza A vaccine, Phase 2b), OVX033 (universal sarbecovirus vaccine, Phase 1 complete), and PANHPVAX (pan-strain HPV vaccine developed with DKFZ). The company is currently clinical-stage and pre-commercial, with future distribution planned through regional pharmaceutical licensing and government procurement channels.
Product overview
Osivax is a clinical-stage biopharmaceutical company developing a portfolio of universal vaccines leveraging its proprietary oligoDOM™ self-assembling nanoparticle platform technology. The company's core product pipeline includes OVX836 (a universal influenza A vaccine targeting the nucleoprotein), OVX033 (a universal sarbecovirus vaccine targeting the nucleocapsid), and PANHPVAX (a pan-strain HPV vaccine developed with dkfz). Osivax combines its T-cell vaccine technology with traditional antibody-based vaccines to develop next-generation vaccines that empower both arms of the immune system. The company is focused on providing broad-spectrum protection against constantly mutating pathogens, starting with influenza while expanding to other infectious diseases.
Differentiator
Problem solved
Functional benefit
Brands
- oligoDOM: Proprietary self-assembling nanoparticles platform technology designed to trigger potent T-cell responses and strong B-cell responses for universal vaccine development
- OVX836
- OVX033
- Asuniva
Products and services
- OVX836 OVX836 is a first-in-class broad-spectrum influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Using Osivax's proprietary oligoDOM™ technology, OVX836 self-assembles into nanoparticles that trigger powerful T-cell and B-cell immune responses, providing broader protection against current and future influenza strains. The vaccine candidate is in Phase 2b clinical development with over 4,000 participants tested across 7 clinical trials to date.
- OVX033 OVX033 is a universal sarbecovirus vaccine candidate that targets the nucleocapsid protein, an internal and invariant antigen. Leveraging the oligoDOM™ technology platform, OVX033 is designed to provide broad-spectrum protection against all current and future sarbecoviruses, including SARS-CoV-2 variants. Phase 1 trial completed enrollment in June 2024.
- oligoDOM™ Technology Platform oligoDOM™ is Osivax's proprietary self-assembling nanoparticle technology platform specifically designed to trigger potent T-cell responses in addition to strong and sustained B-cell responses. The technology transforms small, non-immunogenic native antigens into large nanoparticles that are easily detected by the immune system, enabling development of universal vaccines against conserved internal antigens. The platform is licensed for use in the PANHPVAX HPV vaccine candidate developed with DKFZ.
- PANHPVAX PANHPVAX is a pan-strain human papillomavirus vaccine candidate developed by DKFZ using Osivax's oligoDOM™ technology platform. The vaccine aims to provide protection against almost all carcinogenic HPV types. It is being co-developed under a licensing partnership between Osivax and DKFZ.
Quantifiable outcome
- 84% protection against PCR-confirmed symptomatic influenza compared to placebo in Phase 2a trial
- +3 more outcomes
Companies that use Osivax
Customer profileSegments3 records
Ideal customer profiles3 records
Osivax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Osivax partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and flagship.
- CEPI (Coalition for Epidemic Preparedness Innovations)corePartnership to advance T-cell immunity using CEPI's World-First Adjuvant Library. Osivax will access CEPI's adjuvant library to investigate whether an adjuvanted formulation of OVX836 could enable dose-sparing in pandemic response contexts, potentially maximizing vaccine supply and accelerating access at scale.
- BARDA (Biomedical Advanced Research and Development Authority)flagship$19.5 million award to advance next-generation influenza vaccine OVX836 for pandemic and seasonal preparedness. BARDA funding supports broad-spectrum influenza A vaccine development targeting conserved internal antigens.
- KM BiologicsflagshipExclusive license option agreement for broad-spectrum universal influenza vaccine in Japan. KM Biologics is a Meiji Group company. Agreement provides regional commercialization rights.
- Vaccine Clinical Investigator Center Cochin-Pasteur, APHPcoreFirst-In-Human trial for sarbecovirus vaccine candidate OVX033 conducted at this clinical site.
- NIAID (National Institute of Allergy and Infectious Diseases)coreOver USD 1.5 million grant to support preclinical studies of OVX836 against pandemic influenza strains (H1N1 and H5N1). Studies conducted at CEA in France to evaluate vaccine effectiveness.
- Bill & Melinda Gates FoundationcoreGrant to fund research and development of OVX836, evaluating vaccine efficacy against various influenza strains and potential for long-term protection. Ongoing clinical trials in Belgium and Australia.
- Bpifrancecore€10 million grant to support clinical development of OVX836, a broad-spectrum flu vaccine. Funding used for Phase 2b clinical trial to evaluate vaccine effectiveness against various flu strains.
- NIH/NIAIDcoreAgreement with US National Institutes of Health for preclinical services including refined immunological assessments of OVX836 using flow cytometry analyses to characterize CD4, CD8 and polyfunctionality of T cell immune responses.
- CEA (French Alternative Energies and Atomic Energy Commission)coreResearch partnership for preclinical evaluation of OVX836 vaccine candidate against pandemic influenza strains. CEA conducts vaccine effectiveness studies in France.
- DKFZ (German Cancer Research Center)coreCollaboration for pan-strain human papillomavirus vaccine (PANHPVAX) development using Osivax's oligoDOM™ technology platform. Second license agreement signed April 2018 for clinical development.
- University of Antwerp - Center for the Evaluation of Vaccination (CEV)coreClinical trial partnership for Phase 1 and Phase 2a studies of OVX836. CEV is a WHO Collaborating Centre for control and prevention of infectious diseases, founded by Prof. Pierre Van Damme.
- CEVAC - Center for Vaccinology, Ghent UniversitycoreClinical trial partnership under Principal Investigator Prof. Isabel Leroux-Roels for Phase 2a and Phase 2b trials. Large track record in conducting vaccine trials for numerous infectious diseases.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Osivax competitors and assessment
Company assessmentDirect peers
- BiondVax Pharmaceuticals: Israeli clinical-stage biotech developing M-001, a universal influenza vaccine candidate targeting conserved epitopes. Closest direct competitor in the universal flu vaccine space; serves as a cautionary tale after Phase 3 failure despite multiple Phase 2 successes.
- FluGen: US clinical-stage biotech developing M2SR, a universal influenza vaccine candidate based on live-attenuated single-replication virus. Direct competitor targeting broad influenza protection via conserved antigens.
Broad incumbents
- Moderna: Major mRNA vaccine company developing mRNA-1010 and follow-on mRNA influenza vaccine programs with strain-agnostic claims. Represents the most significant competitive threat to oligoDOM™ positioning and is the benchmark for influenza vaccine platform valuations.
- Sanofi Pasteur: World's largest influenza vaccine manufacturer (Fluzone HD, Flublok), also partnered with Translate Bio on mRNA flu vaccines. Represents the dominant incumbent that any new universal flu entrant must displace or partner with.
- CSL Seqirus: Major global influenza vaccine manufacturer (Fluad, Flucelvax) with cell-based and adjuvanted platforms. Comparable to Osivax as a leading flu vaccine innovator with established global commercial infrastructure.
- GSK: Top-tier global vaccine manufacturer with multiple influenza vaccine franchises (Fluarix, Flulaval) and deep expertise in vaccine adjuvant systems. Likely large-pharma partner or acquirer candidate for Osivax given management pedigree.
- BioNTech: Major mRNA vaccine company with influenza programs and established Pfizer partnership. Represents both a competitive threat (mRNA flu) and a potential partnership/acquisition target given European geographic overlap with Osivax.
Emerging players
- Novavax: Clinical-stage vaccine company using nanoparticle technology (Matrix-M adjuvant, recombinant protein nanoparticles) for influenza and COVID vaccines. Most relevant peer from a nanoparticle platform architecture perspective.
- VBI Vaccines: Clinical-stage biotech using enveloped virus-like particle (eVLP) platform technology for infectious disease and oncology vaccines. Comparable platform-technology peer with multiple vaccine candidates.
- CureVac: European-headquartered mRNA vaccine company with broad infectious disease pipeline including influenza and coronavirus programs. Comparable European biotech with platform-technology vaccine approach.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Osivax social profiles
Digital presenceOsivax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Osivax leadership team
Management profileNumber of profiles
Profiles9 records
Osivax subsidiaries and ownership
Company hierarchySubsidiaries2 records
Osivax funding detail
Funding detailFunding overview
Funding rounds9 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Osivax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Osivax
What does Osivax do?
Osivax develops universal vaccine candidates using its proprietary oligoDOM™ self-assembling nanoparticle platform, which targets highly conserved internal antigens (nucleoprotein/nucleocapsid) to elicit potent T-cell and B-cell immune responses. Its lead candidates include OVX836 (broad-spectrum influenza A vaccine, Phase 2b), OVX033 (universal sarbecovirus vaccine, Phase 1 complete), and PANHPVAX (pan-strain HPV vaccine developed with DKFZ). The company is currently clinical-stage and pre-commercial, with future distribution planned through regional pharmaceutical licensing and government procurement channels.
Is Osivax a public or private company?
Osivax is a private company. It is classified as venture growth investor backed and is currently operating.
When was Osivax founded?
Osivax was founded in 2017. It employs 11 to 50 people.
Where is Osivax based?
Osivax is headquartered in Lyon, France, in the Europe region.
How does Osivax make money?
Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are licensing and Partnership Agreements and government and NGO Grants.
Who are Osivax's main competitors?
Direct peers on record are BiondVax Pharmaceuticals and FluGen. Broad incumbents are Moderna, Sanofi Pasteur, CSL Seqirus, GSK and BioNTech. Emerging players are Novavax, VBI Vaccines and CureVac.
Does Osivax have an API?
No public API is recorded for Osivax.
What industry is Osivax in?
Osivax's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAB, Adult Vaccines. Its NAICS code is 325414 and its SIC code is 2836.